Intensity Therapeutics (INTS) Total Current Liabilities (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Total Current Liabilities came in at $2.2 million in Q1 2026, down 14.72% YoY from $2.6 million in Q1 2025, and up 4.47% on a QoQ basis from $2.1 million in Q4 2025.
Intensity Therapeutics (INTS) Total Current Liabilities (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Total Current Liabilities data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Total Current Liabilities fell 14.72% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 14.72% YoY) and the FY2025 annual result came in at $2.1 million, up 22.28% from the prior year.
- Total Current Liabilities grew to $2.2 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $6.8 million in Q4 2022 to a low of $723966.0 in Q3 2023.
- A 5-year average of $2.8 million and a median of $2.3 million in 2024 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 220.04% in 2024, down 55.67% in 2024.
- Tracing INTS's Total Current Liabilities over 5 years: stood at $6.8 million in 2022, then slumped by 41.94% to $4.0 million in 2023, then sank by 55.67% to $1.8 million in 2024, then advanced by 22.28% to $2.1 million in 2025, then gained by 4.47% to $2.2 million in 2026.
- The last three Total Current Liabilities figures came in at $2.2 million (Q1 2026), $2.1 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 630.93 Mn |
| 10 | Intensity Therapeutics | 12.56 Mn | 12.56 Mn | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.25 Mn |
| Mar 31, 2026 | 2.24 Mn |
| Dec 31, 2025 | 2.15 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 2.16 Mn |
| Mar 31, 2025 | 2.63 Mn |
| Dec 31, 2024 | 1.76 Mn |
| Sep 30, 2024 | 2.32 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Mar 31, 2024 | 2.52 Mn |
| Dec 31, 2023 | 3.96 Mn |
| Sep 30, 2023 | 723,966.00 |
| Jun 30, 2023 | 3.06 Mn |
| Dec 31, 2022 | 6.82 Mn |